Behavioural Health Market Highly Favorable to the Growth Rate by 2028

According to the latest market report published by Future Market Insights titled “Behavioural Health Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018–2028”, the global behavioural health market is expected to expand at 3.4% CAGR over the forecast period 2018-2028.

North America is expected to hold the highest revenue share in the global behavioural health market over the forecast period. Currently, over 43.8 million adults in the U.S. are suffering from mental illness, which is fuelling demand for behavioral health services. Developing economies are witnessing large demand for home care services, day care services, and internet-counselling services, which is further expected to boost revenue growth of the behavioural health market in emerging markets.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5375 

Global Behavioural Health Market: Segmental Analysis & Forecast

The global behavioural health market is segmented based on service type, disorder type, and region. Based on service type the market is segmented into outpatient counselling, intensive case management, home-based treatment services, inpatient hospital treatment, emergency mental health service and others. The inpatient hospital treatment services type segment is expected to represent highest revenue share in the global behavioural health market. Home-based treatment services are expected to gain popularity among people in the coming years and this segment is expected to expand at a CAGR of 4.0% over the forecast period.

Based on disorder type the market is segmented into the anxiety disorder, bipolar disorder, depression, eating disorder, post-traumatic stress disorder (PSTD), substance abuse disorder and others. Among all disorder types, the anxiety disorder segment is anticipated to continue to lead the global behavioural health market due to a high patient pool globally and high adoption of behavioural health therapy among patients suffering from anxiety issues. According to the WHO, globally 260 million people are suffering from anxiety disorder.

Increased exposure to drugs and alcohol among young adults and strengthening insurance coverage policies for mental health are identified as key trends among end users in the global behavioural health market. Furthermore, rehabilitation programs for substance abuse disorder patients, outpatient counselling for ADHD affected children, and campaigns to spread awareness regarding mental disorders and drug addiction, etc. are some of the major factors that are driving the growth of the global behavioural health market. Government initiatives to reduce the burden of mental illness and rehabilitation services by non-government organizations (NGO) are further expected to positively impact revenue growth of the global behavioural health market.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-5375 

Global Behavioural Health Market: Competition Analysis

The global market for behavioural health is fragmented with many local and regional level players operating in the worldwide market. Some of the key players featured in the global behavioural health market report include Acadia Healthcare Co., Inc., Universal Health Services Inc., Magellan Health Inc., National Mentor Holdings Inc., Behavioral Health Services Inc., Behavioral Health Network Inc., North Range Behavioral Health, Strategic Behavioral Health LLC, Seton Healthcare Family (Ascension Health) and Ocean Mental Health Services Inc. etc. among others.

Biologic Excipients Market to Represent a Significant Expansion at 3.6% CAGR During 2018-2028

Future Market Insights (FMI) delivers key insights on the global biologic excipients market in its upcoming report titled “Biologic Excipients Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018 – 2028”. In terms of revenue, the global biologic excipients market is projected to register a CAGR of 3.6% over the forecast period owing to various factors, regarding which FMI offers detailed insights and forecasts in this report.

Global Biologic Excipients Market: Segmental Analysis & Forecast

The global market is segmented based on excipient type, end user and region. Based on excipient type the market is segmented into polymers, sugar alcohols, polysorbates, inorganic salts, amino acids, surfactants and others. Polymers biologic excipients are anticipated to lead the biologic excipients market over the forecast period. Polymer biologic excipients account for the highest revenue share and are anticipated to witness a growth rate of 3.7% over the forecast period.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6982 

By end user, the market is segmented into biopharmaceutical manufacturers, contract research organisations/contract manufacturing organisations, and research organisations. Biopharmaceutical manufacturers is the leading segment in the global biologic excipients market over the forecast period. This segment accounts for a relatively higher revenue share, which is expected to register a CAGR of 6.0% over the forecast period.

Global Biologic Excipients Market: Dynamics

Growth of the global biologic excipients market is primarily driven by rising global demand for medicines, greater uptake of biologics driving demand for parenteral formulations, increasing acquisition of contract research organisations, patent expiration of major blockbuster drugs, growing adoption of advanced drug delivery technologies, increasing research in pediatric formulations, growing demand for extended-release or sustained release formulations, increasing demand for oral solid drug formulations, rising demand from emerging economies pushing local drug production, and increasing per capita healthcare expenditure.

However, lack of proper data documentation on gras status of excipients, regulatory audits restricting supply capacity, regulatory hurdles detering novel excipient development, and stability testing of excipients imposing cost liabilities on drug manufacturers are some factors expected to hamper the growth of the global biologic excipients market over the forecast period.

A key trend witnessed in the biologic excipients market is increasing adoption of continuous processing of biologic excipients, dependence of large drug manufacturers on in-house biologic excipients production, vast proportion of imported excipients leading to production delays, and regulatory harmonisation with respect to gradation of excipients. Furthermore, the growing importance of developing biologic excipients by big players in order to enhance their product portfolio, growing importance for manufacturing authorisation, growing market for topical and parenteral applications and compulsory licensing promoting demand for biologic excipients are the key trends likely to be witnessed in the global biologic excipients market.

Global Biologic Excipients Market: Regional Analysis

The North America regional market is projected to dominate the global biologic excipients market, accounting for a maximum revenue share of the global market by 2017 end. The North America, Western Europe, and Asia Pacific markets accounted for 77.3% of the total biologic excipients market share in terms of value in 2017. Revenue from the market in APEJ is estimated to expand at a CAGR of 4.2% over the forecast period.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-6982 

Some of the key players featured in this report on the global biologic excipients market include BASF Corporation, FMC Corporation, Wacker Chemie AG, Evonik Industries AG, Ashland Global Holdings Inc., Archer-Daniels-Midland Co., Roquette Freres S.A., The Dow Chemical Company, Colorcon Inc., Signet Chemical Co. Pvt. Ltd. This report discusses the individual strategies followed by these companies regarding bringing improvements in their products, creating new manufacturing facilities, market consolidation and advanced R&D initiatives. The report concludes with key takeaways for players already present in the market and new players planning to enter the market.

Bone Screw System Market Poised to Expand at 6.5% CAGR During 2018-2028

Future Market Insights tracks the performance of the global bone screw system market in a new publication titled “Bone Screw System Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028”. The bone screw system market is anticipated to record a year-over-year growth rate of 6.5% and reach a market value of US$ 1,963 Mn in 2028. Titanium will continue to account for the leading market revenue share by Material Type, accounting for 45.0% share of the global bone screw system market in 2018. In this report, the bone screw system market is segmented based on material type, patient anatomy, end user and region.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4050

Bone Screw System Market: Segmental Insights

Lower extremity segment leads the market for bone screw system owing to increasing number of cases registered due to prolonged effects of osteoporosis among the mass population. In contrast, there are limited number of companies conducting research activities for introducing novel products in the market. In terms of revenues, the lower extremity segment is expected to account for the largest revenue share of 39.2% in 2018 and is expected to witness significant growth during the forecast period. This growth in the lower extremity segment is expected to be primarily driven by rising awareness among the geriatric population and increasing number of orthopaedic cases undergoing surgical interventions.

Stainless steel is likely to be the preferred choice of material used in common practice due to its ready availability and cost efficiency as compared to titanium based screws and bioabsorbable material. Titanium holds a major share in the global market currently due to widespread usage. The bioabsorbable material segment has limited adoption in the market due to premium pricing over other bone screw products.

Among end users, hospitals are expected to hold the maximum share in the overall bone screw system market due to the large number of surgical procedures performed in hospitals using bone screws as compared to other end users such as ambulatory surgical centres and clinics. The hospitals end user segment is estimated to hold a market share of 65.6% in 2018.

Bone Screw System Market: Trends

Computer assisted technology is a revolutionary concept used in orthopaedic treatment procedures. Companies are focussing on collaboration with all end users to develop new effective products with better user interfaces. They are involving breakthrough options in this market to initiate a sense of revolution in using more advanced alternatives. In 2016, Surgebright in cooperation with the German Institute for Tissue and Cell Replacement (DIZG) in Berlin developed latest technology that uses real bone material to form a screw. 3D printing is another innovative technology that could be used in developing bone screws in the near future.

Bone Screw System Market: Regional Insights

The report tracks the global bone screw system market across the key geographies of North America, Europe, Latin America, Asia Pacific Excluding China, China and Middle East & Africa. This report assesses the trends driving each regional market and offers analysis and insights about the bone screw system market across specific countries in the assessed regions. North America accounts for a major share in the global bone screw system market and is expected to grow at a CAGR of 7.1% during the period of assessment. North America is projected to be the most lucrative market in the global bone screw system market with an attractiveness index of 2.3 during the forecast period due to the presence of leading manufacturers and implementation of healthcare reforms in the region.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-4050 

Bone Screw System Market: Competition Tracking

The key players operating in the bone screw system market include companies such as Stryker Corporation, Zimmer Biomet Holdings Inc, CONMED Corporation, Arthrex, Orthofix, SMITH & NEPHEW, Johnson & Johnson (DePuy Synthes), Integra LifeSciences, Wright Medical Group N.V, SURGIVAL INTERNATIONAL, Spineology Inc, GPC Medical ltd., Osteogenics Biomedical,  Altimed, JEIL MEDICAL CORPORATION, Fine Science Tools, MEIRA Inc. and Medtronic.

Enzyme Replacement Therapy Market to Touch US$ 13,776.2 Mn Valuation by End of 2018-2028 Period

According to the latest research published by Future Market Insights, the global enzyme replacement therapy market is poised to expand at 6.5% CAGR over the forecast period 2018–2028. The global market for enzyme replacement therapy is expected to exceed US$ 13,776.2 Mn by 2028 end, attesting the highest growth rate by Japan, which is expected to expand at 12.5% CAGR over 2018–2028. Increasing per capita healthcare expenditure in North America is expected to push market revenue growth. The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populous regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global enzyme replacement therapy market.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3167 

Global Enzyme Replacement Therapy Market: Segmentation & Forecast

The global enzyme replacement therapy market has been segmented on the basis of therapeutic condition, route of administration, distribution channel and region. Therapeutic conditions in the enzyme replacement therapy market include fabry disease, gaucher disease, mucopolysaccharidosis, pompe disease, lysosomal acid lipase deficiency and others. Globally, the mucopolysaccharidosis therapeutic condition is the most attractive segment. Injectable segment remains the most lucrative route of administration in the enzyme replacement therapy market. Among all distribution channels for enzyme replacement therapy, speciality treatment pharmacies are expected to be the most lucrative, followed by hospital pharmacies.

Global Enzyme Replacement Therapy Market: Regional Insights

With nearly 25%-30% market share, North America dominated the global enzyme replacement therapy market in 2017, partly due to the presence of leading market players in the region. In developing regions such as Latin America, advancements in medical facilities are helping the region cope with healthcare crisis. Medical facilities in Brazil are equivalent with hospitals in the United States, with some even exceeding American standards. Brazil offers everything from large, full service hospitals to smaller, intimate private clinics. Brazil has developed into a centre of excellence for healthcare in Latin America, with major universities that support research, teaching and training of medical professionals. Western Europe is the second largest market globally and is expected to be valued at US$ 2,893.2 Mn by 2028, with France, Italy and Spain projected to witness significant growth rates. Japan is expected to be the third largest market for enzyme replacement therapy.

Key Research Findings

Enzyme replacement therapy is used in the treatment of rare diseases and the global market is projected to create incremental opportunity of US$ 6,448.3 Mn between 2018 and 2028

When compared to other established markets such as North America, the enzyme replacement therapy markets in Japan and Western Europe are expected to witness fast and steady growth, partly due to the increasing governmental support and growing demand for enzyme replacement therapy for the treatment of rare diseases.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3167 

Global Enzyme Replacement Therapy Market: Competitive Landscape

The global market is highly consolidated owing to the presence of several players. Some of the key players are Sanofi (Genzyme Corporation), Shire, Pfizer, Inc., Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical, Inc., Ultragenyx Pharmaceutical, Inc., Johnson & Johnson Services, Inc., Allergan, Leadiant Biosciences, Inc., and others. Companies in the global ERT market are focussing on strategic initiatives such as alliances and agreements, collaborations, increasing R&D activities, new product launches, joint ventures, partnerships, and mergers & acquisitions to sustain in the competitive global market.

Amniotic Membranes Market will Exhibit a Steady 9.3% CAGR through 2028

According to the latest market report published by Future Market Insights, titled ‘Global Amniotic Membrane Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028’, the global amniotic membrane market is expected to expand at a CAGR of 9.3% over the forecast period 2018–2028.

FMI estimates that the global market for amniotic membrane is to be valued at US$ 955.2 Mn in 2018 and is expected to expand at CAGR of 9.3% over 2018–2028, to surpass US$ 2,322 Mn by 2028 end. Based on product type, the cryopreserved amniotic membrane segment dominated the global amniotic membrane market, with over 70% value share in 2017. The segment is expected to grow at above 9% CAGR over the forecast period of 2018–2028. North America is expected to maintain its dominance in the global market due to regulatory approvals of several new products in the U.S.

Population of all age groups has emerged as a prominent consumer base, characterised by untapped product segments for amniotic membranes to offer effective wound healing and eye surgeries. This has prompted the amniotic membrane product manufacturers to capitalize on the emerging latent opportunity. The companies in the market are optimistic with regard to increasing amniotic membrane transplants and increasing demand for amniotic membrane products around the world, particularly in North American countries. It is more than likely that over the span of the next four to five years, the companies focus on developing innovative products and designing market level strategies to leverage the potential opportunities emerging in parallel with growing human population with various chronic diseases.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5044

Amniotic membrane products such as Amniotic Allograft Membrane and Amniotic Allograft Suspension used to treat surgical wounds and defects of the corneal epithelia have gained traction over the last two decades. The major types of amniotic membranes such as cryopreserved amniotic membrane and lyophilized amniotic membrane have evolved back in the 1990s, but they became significant and the market for amniotic membranes to be used on humans boomed over the past fifteen years.

The global amniotic membrane market has been segmented on the basis of product type, application, end user and regions. Globally, cryopreserved amniotic membrane is the most attractive segment from manufacturers’ point of view. Cryopreserved amniotic membrane is majorly used in ocular surface eye surgery owing to its positive effect on wound healing due to its anti-inflammatory property. Among all end users of amniotic membrane, high demand for amniotic membrane is expected to come from the hospitals segment due to rising application of amniotic membrane in advanced surgical healing.

By volume, the global amniotic membrane market is expected to expand at 11.4% over the forecast period of 2018–2028. With nearly 43% market value share, North America dominated the global amniotic membrane market in 2017, partly due to penetration of newly approved products in the U.S. Western Europe, the second large market globally, with U.K., France and Germany being countries with high growth rates., is expected to gain 110 BPS in its market share over 2018–2028. APEJ is expected to be the third large market for amniotic membrane. APEJ and China collectively are expected to contribute over 15% share in the global market by 2028 over 2018.

The market for amniotic membrane is highly consolidated with top 5 players contributing over 60% of the revenue share in 2017. Examples of some of the key players identified in the global market are Integra LifeSciencesm Inc., MiMedx Group, Inc., Alliqua BioMedical, Inc., Skye Biologics Inc., Katena Products, Inc., Tissue-Tech Inc., Amnio Technology, LLC, Applied Biologics LLC, Human Regenerative Technologies, LLC, etc. Depth of research, along with proper documentation and statistical validation are factors that could determine a player’s success in the global amniotic membrane market

Some of the key points identified in global amniotic membrane market are:

• FMI forecasts the global amniotic membrane market to grow at a CAGR of 9.3% over the forecast period by 2028 end. The growth in revenue generation across the amniotic membrane market is registered on the account of rise in amniotic membrane transplants in both developed and developing economies.
• The hospitals segment has proved to be the leading end user segment on account of increase in number of amniotic membrane transplants, growing awareness among the people about the benefits of the amniotic membrane transplant.
• Ease of FDA approval for novel and innovative amniotic membrane allografts coupled with adoption of amniotic membrane for varied applications would boost the revenue growth in Germany & the U.S. markets.
• Most often, apart from major applications including surgical wound and ophthalmology, the use of amniotic tissue in orthopaedic surgery, sports medicine and podiatry treatment has increased in the recent years.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-5044

• The amniotic membranes used majorly to treat human surgical wound needs to be FDA approved, thus amniotic membrane manufacturers focus on getting fast FDA approvals.

Disposable Laparoscopic Instruments Market Poised to Register 5.7% CAGR through 2028

Future Market Insights (FMI) delivers key insights on the global disposable laparoscopic instruments market in its upcoming outlook titled “Disposable Laparoscopic Instruments Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028”. In terms of value, the global disposable laparoscopic instruments market is projected to register a healthy CAGR of 5.7% during the forecast period due to various factors, regarding which FMI offers vital insights in detail. Increasing demand for minimally invasive procedures is expected to bolster the overall growth of the disposable laparoscopic instruments market globally.

The global disposable laparoscopic instruments market is segmented on the basis of product type, indication, end use and region. On the basis of product type, the market has been segmented into laparoscopic scissors, laparoscopic hooks, grasping forceps & dissectors, trocars, laparoscopic suction / irrigation devices and others. The trocars product segment is expected to register impressive CAGR of 5.4% during the forecast period.

Laparoscopy is a minimally invasive surgical technique performed through a keyhole incision. A small camera along with a light source attached to a tube enables surgeons to manoeuvre special disposable laparoscopic instruments to the target area and carry out the surgery. This technique is mainly preferred for carrying out surgeries related to the pancreas, liver, colon and bile duct. The use of disposable laparoscopic instruments reduces the risk of infection during surgery. Laparoscopic surgery refers to surgical procedures that are performed through one or multiple small incisions, rather than through a larger incision through the abdominal wall. The number of surgeries is increasing across the globe, more then 15–16 million laparoscopic surgeries are performed across the globe. This directly boosts the demand for disposable laparoscopic instruments as they are safe with no chances of infection. However, in the reusable laparoscopic instruments the chances for infection is high as the sterilization process is done manually in individual hospitals.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3166 

On the basis of indication, the market is segmented into general surgery, bariatric surgery, colorectal surgery, urology surgery, gynaecologic surgeries and others. Gynaecologic surgeries is expected to dominate the overall disposable laparoscopic instruments market throughout the forecast period. It is expected to witness to have US$ 2,122.7 Mn by 2028 end. On the basis of end users, the global disposable laparoscopic instruments market is segmented into hospitals, ambulatory surgical centres and specialty clinics. In terms of end use, the hospitals segment is expected to witness high growth during the forecast period.

Reducing pricing for market pick up, awareness programs in emerging countries, growing demand for minimally invasive therapies and technological advancement are factors expected to drive the global disposable laparoscopic instruments market over the forecast period.

This report covers trends driving the growth of each segment and offers analysis and insights of the potential opportunities offered in the disposable laparoscopic instruments market in all regions of the world. North America is expected to dominate the market throughout the forecast period. Foray of leading North American companies into the disposable laparoscopic instruments market over the last few years is a factor expected to boost the overall sale of these devices in the region. In terms of value, APEJ is expected to witness significant growth during the forecast period. Significant investments in healthcare infrastructure, increasing patient pool along with increasing geriatric population in APEJ are factors expected to boost the revenue growth of the disposable laparoscopic instruments market in the region.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3166 

The key players in the global disposable laparoscopic instruments market include B. Braun Melsungen AG, Medline Industries, Inc., Stryker Corporation, Ackermann Instrumente GmbH, ASFS Medic’s company, Medino GmbH, Péters Surgical, Medtronic, Mediflex Surgical Products and Grena LTD.

Pharma-grade Synthetic Camphor Market size is anticipated to be valued at US$ 532.0 Mn, by 2028

According to the latest research by the company, the global pharma-grade synthetic camphor market size is anticipated to be valued at US$ 532.0 Mn, by 2028 end. The report on pharma-grade synthetic camphor market further projects significant growth potential with average year-on-year growth rate pegged at 4.1% through 2028.

Growing demand for topical pain management products is expected to propel the growth of pharma-grade synthetic camphor market. Pharma-grade synthetic camphor is used in many topical analgesic products such as oils, ointments, chest rubs, and gel. These pharma-grade synthetic camphor pain management products are experiencing significant growth due to lesser side effect compare to oral analgesic and expanded retail channel access. Increasing self-medication rate and availability of cost-effective camphor contained OTC analgesic favors the growth of pharma-grade synthetic camphor market growth. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7564

Growing incidence of infectious diseases such as cold, flu augmented the use of cold sore remedies, nasal decongestants, topical expectorants etc. which in turn would drive the growth of pharma-grade synthetic camphor market. Increasing use of private labeled topical products containing camphor push the demand for pharma-grade synthetic camphor. Private label analgesic is gaining popularity in the U.S. market as they do not require FDA approval and strong promotion activities by retailers. Walgreens Ultra Strength Muscle Rub (4% camphor), Salonpas pain relieving patch (1.2% camphor) are the examples of private label analgesic which contain camphor. Surge in commodity export, economic growth and production capacity are expected to boost the growth of pharma-grade synthetic camphor market.

However, regulatory restrictions on the use of camphor in the medicine of pharmaceutical products would considerably impact the growth of pharma-grade synthetic camphor market. Moreover, increasing raw material prices are expected to hamper the growth of pharma-grade synthetic camphor market. Thus, growing prices of raw materials i.e. alpha pinene or turpentine oil is a major challenge for the manufacturers of pharma-grade synthetic camphor.

Company has segmented the global pharma-grade synthetic camphor market into formulation, application, distribution, and regions. Based on the formulation, pharma-grade synthetic camphor market is segmented into topical and inhalation. The topical segment is expected to represent a highest revenue share in pharma-grade synthetic camphor market as high number of marketed products and vast applications. Applications of pharma-grade synthetic camphor included in the report are respiratory disorders applications, muscular rheumatism, counterirritant & antipruritic and others (topical analgesic, cold sores, minor burns, antifungal, hemorrhoids, topical antitussive & expectorant, astringent, rubefacient, etc.). Others segment expected to contributes highest market value in global pharma-grade synthetic camphor market. Based on the distribution channel, pharma-grade synthetic camphor market is segmented into conventional B2B and online B2B channel.  In terms of revenue, conventional B2B segment would hold significant revenue share in pharma-grade synthetic camphor market over the forecast period.

On the basis of region, the global pharma-grade synthetic camphor market has been segmented into North America, Latin America, Western Europe, Eastern Europe, the Asia Pacific excluding China & Japan, China, Japan, and the Middle East & Africa. North America is expected to contribute highest revenue share in global pharma-grade synthetic camphor market. The demand of pharma-grade synthetic camphor has increased in North America, as increasing production of camphor contained private label and OTC products. China is expected to witness the highest growth rate in pharma-grade synthetic camphor market due to presence of the larger number of pharma-grade synthetic camphor manufactures. Pharma-grade synthetic camphor manufactures are mainly concentrated in China and India and they export their chemicals to the U.S. and Europe. Moreover, due to its growing contribution to the global industry, Asia Pacific is emerging as a focused destination for global manufacturers of camphor and related chemicals.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7564

Report tracks some of the key companies operating in the global pharma-grade synthetic camphor market. Representative players included in the global pharma-grade synthetic camphor market report are Merck KGaA, Oriental Aromatics Limited, Saptagir Camphor Limited, Mangalam Organics Limited, Nippon Fine Chemical Co., Ltd., Rochem International, Inc., Spectrum Chemical Mfg. Corp., Aldon Corporation, Prinova Group LLC. and Fengchen Group Co., Ltd. Manufactures are focusing on improvement of the supply chain which expected to provide huge opportunities to them over the forecast period.

Cell Line Development Market size is anticipated to account for over US$ 7,200 Mn, in terms of value, by 2028 end

According to International Agency for Research on Cancer, the number of new cancer cases per year is expected to rise to 23.6 million by 2030 globally. In recent times, cell line development and its applications are considered as potential tools in oncology research. Cell lines are projected to be used for development of new treatment pathway for various disease including cancer and neurological diseases. According to a latest research by Future Market Insights (FMI), the global cell line development market size is anticipated to account for over US$ 7,200 Mn, in terms of value, by 2028 end. The report on cell line development market further projects significant growth potential with CAGR at 7.2% through 2028.

Rapid increase in prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.

In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST). Regenerative medicines are the next generation treatment solution and Cell Line Development or Cell Culture is a vital part for regenerative medicine. Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-7566

The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market.

Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, type of cell line and region.

Product type segment in cell line development market is segmented into media and reagents, equipment and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. Reagent and media segment in cell line development market is expected witness noteworthy growth in terms of revenue owing to rapid increase in demand in cell culture and cell based assays.

Cell line development market by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipate to witness significant growth in overall cell line development market. This growth of mammalian cells segment in cell line development market is driven by increased production of biologics drugs which require mammalian cells. Increasing antibody production is the major driving factor behind the growth of mammalian cell lines segment in cell line development market. Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. 

For example, Gaucher’s disease, which is a genetic disorder characterized by lack of β-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produces in mammalian cell lines. Mammalian cell lines are also useful in production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease causing agents in the body. For example Under cell line type segment in cell line development market, recombinant cell line development are the most demanding type of cell line due to large application in biologics production, protein interaction, gene activation, toxicity testing and drug screening. Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period

North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market. The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-7566

FMI’s report tracks some of the key companies operating in the cell line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.

Customer Experience Platforms Market: Growing Adoption by Small, Medium, and Large Enterprises to Fuel Revenue Growth

According to a recent market report published by FMI titled “Customer Experience Platforms Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028” the global customer experience platforms market was valued at US$ 5,262.6 Mn in 2017, and is expected to register a CAGR of 12.7% from 2018 to 2028.

Customer experience platforms facilitate interactions with customers to get feedback about the products or services that they are using. Customer experience platforms are used for viewing a customer’s experience and then improving the services of an enterprise according to the feedback received. Customer experience platforms are used for tracking customer interactions throughout the customer purchase process as well as the post-purchase process. The adoption of customer experience platforms across different organisations is increasing as it allows them to capture insights from customer interactions as well as optimise the response from each interaction point. The data collected from customer experience platforms is used by enterprises to improve customer loyalty and improve customer lifetime value.

A global increase in competition is posing significant challenges for enterprises when it comes to customer retention as every other enterprise is offering something extra to customers to attract them. To sustain in such competition, the need for existing customer retention and new customer attraction is increasing, and these some of the key factors fuelling the customer experience platforms market.

The rising need for customer satisfaction for improving brand loyalty is one of the prime factors that is significantly driving the customer experience platforms market. Enterprises are leveraging customer experience platforms for creating brand attachment among their customers by delivering real-time feedback and contact centre facilities. Constant advancements in technology are resulting in the increasing adoption of smartphones, which has eased the process of customer experience platforms and increased the accessibility of customers to customer experience platforms. The vendors of customer experience platforms are introducing new innovations and integrations to enhance the usability of customer experience platforms. This factor is expanding the application areas of customer experience platforms. For example, OpenText offers a customer experience platform for enterprises across different industry verticals. Some of the features of this customer experience platform include Customer Communication Management (CCM), forms automation, digital asset management and marketing & workforce optimisations, among others. Due to the availability of these features, customer experience platforms are becoming more popular as enterprises are also able to perform other operations with the help of customer experience platforms to improve the quality of service delivery.

The global customer experience platforms market is categorised on the basis of interaction point, platforms, enterprise size, industry, deployment and region. On the basis of deployment, the customer experience platforms market is segmented into on-premise and cloud deployment. Among the customer experience platforms deployment segments, the cloud deployment segment has a major market share due to an increase in the preference for cloud deployed software by enterprises. Cloud deployment for customer experience platforms is preferred for implementing a secure, fast and efficient feedback process.

On the basis of platform, the customer experience platforms market is segmented into Windows, iOS and Android. Among the platform segments of the customer experience platforms market, Android has a major market share due to the rapid penetration of Android smartphones.

On the basis of vertical, the global customer experience platforms market is segmented into IT & Telecommunication, BFSI, healthcare, consumer goods & retail, hospitality, transportation & logistics, media & entertainment and government. The revenue contribution from the consumer goods & retail segment of the customer experience platforms market is expected to expand at a CAGR of 15.1% during the forecast period due to the rapid adoption of this software by enterprises in the consumer goods & retail industry vertical for maintaining the quality of products and services offered by them. The adoption of customer experience platforms is also fuelled by the increasing competition in the consumer goods & retail industry.

On the basis of enterprise size, the global customer experience platforms market is segmented into small enterprises, medium enterprises and large enterprises. The revenue contribution from the large enterprises segment of the customer experience platforms market is expected to expand at a CAGR of 13.3% during the forecast period. This can be attributed to the fact that established brands and emerging brands primarily include large enterprises, and these enterprises are increasingly investing in solutions to retain existing customers as well as attract new ones. This trend is one of the key factors fuelling the demand for customer experience platforms among large enterprises.

On the basis of interaction point, the customer experience platforms market is segmented into stores, websites, email, call centre, mobile apps and social media. These interaction points are used by enterprises while taking feedback from customer experience platforms. The revenue contribution from the mobile apps segment of the customer experience platforms market is expected to expand at a CAGR of 15.2% during the forecast period due to the increasing preference for mobile apps by customers for shopping as well as surfing. Moreover, the constant availability of mobile phone users for giving & receiving feedback as well as the ease of usage of these devices are among factors fuelling the growth of this segment of the customer experience platforms market.

The customer experience platforms report also covers the trends that drive each segment, as well as offers analysis & insights regarding the potential of the customer experience platforms market in regions such as North America (U.S. and Canada), Latin America (Brazil, Mexico and the rest of Latin America), Western Europe (Germany, Italy, France, Spain, U.K., BENELUX and the rest of Western Europe), Eastern Europe (Russia, Poland and the rest of Eastern Europe), China, Japan, SEA and other APAC (India, ASEAN, Australia, New Zealand and the rest of SEA), and MEA (GCC Countries, Turkey, North Africa, South Africa and the rest of MEA). Revenue contribution from the North America segment of the customer experience platforms market is expected to expand at a CAGR of 13.1% during the forecast period due to the high adoption of customer experience platforms.

Some key vendors of customer experience platforms include: IBM Corporation, Zendesk, SAS Institute, Huawei Corporation, Oracle Corporation, Qualtrics, Cisco Systems, Inc., OpenText Corporation, Tech Mahindra, TCS, Adobe Systems Incorporated, Software AG, Avaya

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-7587

Global Prefilled Formalin Vials Market is projected to account for over US$ 515.8 Mn, in terms of value, by 2028 end

The growth of the healthcare industry is expected to play a vital role in shaping the future prospects of the prefilled formalin vials market. Formalin is a derivative of formaldehyde, and prefilled formalin vials are used for tissue fixation. According to a latest research by Future Market Insights (FMI), the global prefilled formalin vials market is projected to account for over US$ 515.8 Mn, in terms of value, by 2028 end. The report on prefilled formalin vials market projects significant growth potential with average compound annual growth rate pegged at 4.1% through 2028.

Prefilled Formalin Vials Market: Overview

According to the new European rules and guidelines, it is essential to protect the environment and the health of the workers who work in an environment where they are directly exposed to aldehydes. Emission of formalin fumes in pathology labs can lead to serious health hazards. The discharge of these fumes can be avoided by using chemical hoods, particularly in operation theatres, where formalin is mostly used. The need to lower the level of formalin emission has surged the demand for prefilled formalin vials, and the growth of the prefilled formalin vials market. In the medical ambulatories including ambulatory surgical centers where small biopsies are performed, the challenges associated with formalin usage are dealt primarily by using prefilled formalin vials or tubes. Direct exposure to formalin increases the risk of developing cancer. Prefilled formalin vials limit the risk of direct exposure to formalin. This factor, in particular, is likely to play an instrumental role in driving the growth of the prefilled formalin vials market.

Request Report Sample@  https://www.futuremarketinsights.com/reports/sample/rep-gb-7582

The prefilled formalin vials can be used for diversified applications in distinct end-use settings such as forensic labs, CROs, emergency medical services, diagnostic laboratories, and veterinary laboratories, among others. Formalin being a cost-effective method of histopathological diagnosis plays a vital role in the healthcare industry, as it cuts down the unnecessary costs associated with the procedural changes related with the usage of new alternative fixatives. In the European Union (EU) in 2017, 971,000 workers were estimated to be exposed to formaldehyde above the background level. Out of these, 175,380 were registered in Italy. Formaldehyde is commonly known to have acute toxicity, resulting in sensory irritation in the eyes and upper respiratory tract. The demand for formalin from veterinary clinics and forensic laboratories has remained stable, but is likely to decline in the near future. This is primarily to due to strict regulations regarding the usage of formalin across the globe.

Prefilled Formalin Vials Market: Segmental Analysis

Prefilled formalin vials are commercially available in different packaging forms in the global prefilled formalin vials market. Of these, 90 – 500 mL prefilled formalin vials are high in demand in the global prefilled formalin vials market, owing to the fact that there is no alternative fixative validated to be served as formalin replacement. Likewise, the 40 – 60 mL prefilled formalin vials segment is also projected to hold significant revenue share as their adoption is increasing in diagnostic and forensic laboratories. Diagnostic laboratories and CROs performing cancer research and diagnostics are the primary consumers of prefilled formalin vials. According to FMI, the contract research organizations segment accounted for over 28.8% revenue share in the global prefilled formalin vials market in 2017.

Formalin is a cost-effective method of histopathology diagnostic in the West and East Asia, owing to which the demand for prefilled formalin vials has increased in the region. Furthermore, the growing incidence of cancer in Asia Pacific due to changing lifestyle of people is likely to boost the growth of the prefilled formalin vials market in the region. Presence of large number of companies with sole focus on providing high-quality prefilled formalin vials and rising disposable income in Japan are factors expected to surge the demand for prefilled formalin vials in the country.

FMI has segmented the global prefilled formalin vials market based on product type and end users. In terms of revenue, the 90 – 500 mL product type segment in the prefilled formalin vials market is expected to hold significant share over the forecast period. In contrary, the <10 mL product type segment in the prefilled formalin vials market is expected to exhibit limited investment opportunities, in terms of revenue, through 2028.

Request to Browse Report Customization @  https://www.futuremarketinsights.com/customization-available/rep-gb-7582

Prefilled Formalin Vials Market: Key Players

The report tracks some of the key companies operating in the prefilled formalin vials market, such as Diapath S.p.A, Histo- Line Laboratories Srl, Cardinal Health, Inc., Leica Microsystems Sales GmbH (Leica Biosystems Nussloch GmbH), Genta Environmental Ltd., Carl Roth GmbH + Co. KG, Magnacol Ltd., Serosep Limited, Ultident Scientific and Solmedia Limited.

Smart Insulin Pens Market To Bring In Revenues US$ 4 Mn By 2027

Increasing pool of diabetic patients witnessed across the globe has prompted leading manufacturers of medical devices towards development of ground-breaking products. Smart insulin pens are among such devices that have revolutionised the global market for diabetic injection pens. A recent study published by Future Market Insights projects that the global smart insulin pens market, which is currently valued at US$ 0.86 Mn, will expand vigorously at 17.9% CAGR through the end of 2027. During this ten-year forecast period, the global demand for smart insulin pens is estimated to surge rapidly as medical device manufacturers will be actively adopting advanced technologies that deliver cutting-edge devices.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1827 

While the parent market – global diabetic injection pens market – is presently worth US$ 4.9 Bn, contribution of revenues arising from global sales of smart insulin pens will remain minimal. Nevertheless, the global smart insulin pens market will bring in more than US$ 4 Mn revenues by the end of 2027. The report, titled “Smart Insulin Pens Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,” also reveals that Europe will emerge as a dominant region for growth of global smart insulin pens market.

Sales of smart insulin pens across European countries are anticipated to bring in over US$ 2.4 Mn by end of 2027. Meanwhile, awareness regarding smart insulin pens is expected to rise robustly across the US and Canada. North America’s smart insulin pens market is, thus, estimated to register revenue growth at a staggering 26.7% CAGR. Through 2027, sales of smart insulin pens across Asia-Pacific region are also projected to gain traction, bringing in a little over US$ 1.2 Mn in revenues.

Key Trends Driving the Demand for Smart Insulin Pens

A crucial factor fuelling the global sales of smart insulin pens is higher dependency of patients & medical professionals on data obtained from clinical trials. Conventional devices are unable to offer facilities that are provided through smart insulin pens. The demand for smart insulin pens is also driven by preference of health insurers towards outcome-based compensation models. Moreover, medical device manufacturers are looking at profitable opportunities arising from rising adoption of medical management processes, increasing development of insulin adherence programs, and higher demand for patient-centric devices. It has been estimated that during the forecast period, the global market for smart insulin pens will witness active participation from three medical device manufacturers – Companion Medical Inc., Emperra GmbH E-Health Technologies and Digital Medics Pty Ltd.

The report further reveals that a majority of smart insulin pens sold across the world will be purchased for treatment of type II diabetes. The demand for smart insulin pens among type I diabetics is expected to remain considerably lower, procuring global revenues of just over US$ 700,000. Connectivity of smart insulin pens is also observed as a key aspect impacting the market’s growth. And, the report projects the global smart insulin pens market to remain equally split between Bluetooth and USB-connected pens through the end of 2027.

The report also expects clinics and ambulatory surgical centres (ASCs) based across the globe as the largest distribution channels for smart insulin pens. In 2017, close to 88% of global smart insulin pens revenues are likely to be accounted by clinics and ASCs. On the other hand, proliferation of online commercial platforms will also play a key role in distribution of smart insulin pens. Throughout the forecast period, e-Commerce distribution channels are expected to exhibit revenue growth at more than 24% CAGR.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1827 

Safety Needles Market Would Reach US$ 7,765.7 Mn by 2027

The sole purpose of designing safety needles was to avoid needlestick injuries while collecting fluids and delivering drugs to the body. The key players of global market for safety needles are enhancing their product portfolio by focusing on production of innovative needles with safety features. These players include B. Braun Melsungen AG, Novo Nordisk A/S, Medtronic, and Becton, Dickinson and Company. Becton, Dickinson and Company holds its dominance in the overall market with around 50% share, followed by Medtronic and Novo Nordisk AS. Future Market Insights’ recent report profiles Smith Medical and Argon medical Inc. as emerging safety needle manufacturers, while Terumo Medical Corporation and Boston Scientific Inc. are recognised as mid-level players in the global safety needles market.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2029 

Rising Focus on Use of Prefilled Syringes Fuelling the Demand

At present, value of the global safety needles market is estimated to be s worth US$ 3,752.2 Mn, and it is estimated to reach US$ 7,765.7 Mn by 2027-end, witnessing a CAGR of 6.9% during this forecast period. The growing focus on utilization of prefilled syringes for treatment of several ailments is fuelling the demand for safety needles across the globe. Factors such as changing lifestyle habits, exposure to hormones and infection by HCV are expected to result in gynaecological cancers. Rising incidence rate of gynaecological cancers, coupled with higher presence of lower-back problems in regions such as the US are driving the demand for spine needles and other types of safety needles.

Trends Observed in the Global Safety Needles Market

Leading companies are participating in campaigns in co-ordination with governments of several economies for raising awareness about unsafe use of reusable needles among patients. Increasing prevalence of HIV & blood-borne diseases, owing to needle injuries, has also urged the companies for development of needles with enhanced safety features.

Key findings from FMI’s Report Include

• Hypodermic needles, as a product, will dominate the market, and is expected to account for 18.1% share during the forecast period. However, biopsy needles are expected to witness fastest revenue growth at 8.6% CAGR.
• Hospital pharmacies are estimated to account for more than half of safety needles being distributed globally, while private clinics are expected to garner over US$ 1,300 Mn through 2027.
• Drug delivery application of safety needles is expected to gain 242 BPS in its market share. In addition, sample collection is projected to create an absolute $ opportunity of around US$ 1,840 Mn in 2017 over 2016.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-2029 

APEJ – Fastest-Growing Safety Needles Market in World

Around 24% market share is estimated to be held by Western Europe by the end of 2027, while APEJ is expected to register fastest growth in the global market for safety needles. In contrast, Eastern Europe is poised to depict a sluggish growth during the forecast period, while North America is will remain the outright dominant region in the global market for safety needles.